Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020505 (
hyperphagia
)
6,116
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Orphanin FQ/nociceptin binds with high affinity to the
orphan opioid receptor
-like/K-3 (ORL1/KOR-3) clone, and stimulates feeding. The present study demonstrated that antisense oligodeoxynucleotides directed against either exons 1, 2 or 3 of the ORL1/KOR-3 clone reduced orphanin FQ/nociceptin-induced
hyperphagia
. A missense probe was ineffective. Naltrexone dose-dependently reduced orphanin FQ/nociceptin-induced
hyperphagia
. These data suggest that the receptor responsible for orphanin FQ/nociceptin-induced
hyperphagia
is encoded by the ORL1/KOR-3 clone.
...
PMID:Orphan opioid receptor antisense probes block orphanin FQ-induced hyperphagia. 966 88
Binge eating is a dysregulated form of feeding behavior that occurs in multiple eating disorders including binge-eating disorder, the most common eating disorder. Feeding is a complex behavioral program supported through the function of multiple brain regions and influenced by a diverse array of receptor signaling pathways. Previous studies have shown the overexpression of the opioid neuropeptide nociceptin (orphanin FQ, N/OFQ) can induce
hyperphagia
, but the role of endogenous
nociceptin receptor
(
NOP
) in naturally occurring palatability-induced
hyperphagia
is unknown. In this study we adapted a simple, replicable form of binge eating of high fat food (HFD). We found that male and female C57BL/6J mice provided with daily one-hour access sessions to HFD eat significantly more during this period than those provided with continuous 24h access. This form of feeding is rapid and entrained. Chronic intermittent HFD binge eating produced hyperactivity and increased light zone exploration in the open field and light-dark assays respectively. Treatment with the potent and selective
NOP
antagonist SB 612111 resulted in a significant dose-dependent reduction in binge intake in both male and female mice, and, unlike treatment with the serotonin selective reuptake inhibitor fluoxetine, produced no change in total 24-h food intake. SB 612111 treatment also significantly decreased non-binge-like acute HFD consumption in male mice. These data are consistent with the hypothesis that high fat binge eating is modulated by
NOP
signaling and that the
NOP
system may represent a promising novel receptor to explore for the treatment of binge eating.
...
PMID:Nociceptin receptor antagonist SB 612111 decreases high fat diet binge eating. 2703 50